WO2007006543A1 - Camptothecin analogues, process for their preparation, use and formulations containing them - Google Patents
Camptothecin analogues, process for their preparation, use and formulations containing them Download PDFInfo
- Publication number
- WO2007006543A1 WO2007006543A1 PCT/EP2006/006760 EP2006006760W WO2007006543A1 WO 2007006543 A1 WO2007006543 A1 WO 2007006543A1 EP 2006006760 W EP2006006760 W EP 2006006760W WO 2007006543 A1 WO2007006543 A1 WO 2007006543A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- residue
- arom
- straight
- branched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to novel camptothecin analogues modified in the E ring through lactone-opening with polyamines to give ⁇ -hydroxy amides.
- the ⁇ -hydroxy function i.e. the hydroxy group at the 17- position, can be removed or esterified with CpC 24 straight, branched, saturated or unsaturated acyl residues.
- R 1 is a straight or branched polyamino residue, optionally functionalized by acylation or alkylation of the amino groups, with more than 2 nitrogen atoms;
- R 2 is H, -OR 3 ;
- R 3 is H or a Cj-C 24 straight or branched, saturated or unsaturated acyl residue
- R 4 is H, straight or branched Cj-C 4 alkyl, hydroxyalkyl, aminoalkyl or cyano;
- R 5 and R 6 can be H, -OH or -OCH 3 .
- spermine and spermidine are preferred.
- the product is salified with suitable organic or inorganic acids, preferably trifluoroacetic, oxalic, tartaric or hydrochloric acid.
- the 17- position is preferably esterified with activated derivatives of acetic, ximeninic, c/s-4,7, 10, 13, 16, 19- docosahexenoic or c/s-5,8, 1 1, 14- eicosapentaenoic acid.
- the products of the invention are usually synthesized from camptothecin, or from analogues thereof suitably functionalized at the 7-, 9- and 10- positions by reaction with a suitably protected polyamine.
- the reaction is usually performed in polar aprotic solvents, in the presence of a base.
- Upon completion of the reaction the mixture is neutralized with acids and extracted with an organic solvent.
- the crude obtained after evaporation of the solvent can be purified or used as such for subsequent functionalization at the 17- position.
- the polyamine is preferably protected with a t-butoxycarbonyl (Boc) or a carbobenzyloxy (CBz) group.
- the protected polyamine is prepared as described in literature.
- the esterification of the 17- position is preferably performed on the crude precursor by acylation with the selected acyl chloride in pyridine.
- the removal of the 17-hydroxy group is instead accomplished by hydrogenolysis with Pd(C) in methanol under the conditions described in greater detail in the examples.
- a simplified procedure for the preparation of the salts consists in the use of CBz protected polyamines, and deprotection through hydrogenation in the presence of stoichiometric amounts of the selected acids.
- the integrity of the E-ring is commonly deemed crucial for the cytotoxic activity of camptothecin analogues
- the compounds of the present invention maintain an interesting cytotoxic in vitro activity and still inhibit topoisomerase I.
- the products of the invention show activity against the H460 lung tumor model comparable to substances are already used in clinic, such as topotecan, and other active principles currently under clinical investigation.
- the advantage of the compounds of the invention consists in lower toxicity compared with known products and in higher tolerability, which allow a broader therapeutic window.
- N 2 ,N 3 -Di-t-butoxycarbonylspermidine (2.8 g, 8.1 mmol), prepared according to the procedures reported in literature, is added to a suspension of camptothecin (700 mg, 2.01 mmol) in dry pyridine (50 ml), under nitrogen atmosphere.
- the reaction mixture is heated to 8O 0 C to obtain a clear yellow mixture.
- After 3 days at 8O 0 C the mixture is cooled and washed with 5% HCl, extracted with CHCl 3 and dried over Na 2 SO 4 .
- a suspension of 7-ethylcamptothecin (3 g, 7.9 mmol) in dry pyridine is added with N 2 ,N 3 -dibenzyloxycarbonylspermidine (6.5 g, 15 mmol).
- the mixture is sonicated at 55°C for 12 hrs.
- Pyridine is then removed by distillation under reduced pressure at room temperature and the residue is dissolved in dichloromethane (20 ml), washed with a 5% citric acid solution (2x50 ml) and then with water (20 ml).
- Product E (500 mg, 0.6 mmol) is hydrogenated in the presence of succinic acid (142 mg, 1.2 mmol) in acetonitrile (20 ml) over 5% Pd/C (165 mg), using the same procedure as in example VI.
- Compounds G and H are obtained as 1 : 1 mixture with 91% overall yield.
- the products are separated by flash chromatography.
- Product E (400 mg, 0.48 mmol) is hydrogenated over 5% Pd/C (5%) (100 mg) in the presence of oxalic acid (121 mg, 0.96 mmol) in acetonitrile (20 mL) using the same procedure as in example VI. 234 mg (74.7%) of product I are obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to novel camptothecin derivatives of general formula (I) in which R1 is a straight or branched polyamino residue, optionally functionalized by acylation or alkylation of the amino residues with more than 2 nitrogen atoms; R2 is H, -OR3; R3 is H or a straight or branched C1-C24 saturated or unsaturated acyl residue; R4 is H, straight or branched C1-C4 alkyl, hydroxyalkyl, aminoalkyl or cyano; R5 and R6 can be H, OH or OCH3. The compounds of the present invention can be conveniently administered for the therapy of tumors, in the form of suitable pharmaceutical formulations.
Description
CAMPTOTHECIN ANALOGUES, PROCESS FOR THEIR PREPARATION, USE AND FORMULATIONS CONTAINING THEM
Disclosure of the invention
The present invention relates to novel camptothecin analogues modified in the E ring through lactone-opening with polyamines to give ω-hydroxy amides. The ω-hydroxy function, i.e. the hydroxy group at the 17- position, can be removed or esterified with CpC24 straight, branched, saturated or unsaturated acyl residues.
The compounds of the present invention have general formula (I)
(I) wherein
R1 is a straight or branched polyamino residue, optionally functionalized by acylation or alkylation of the amino groups, with more than 2 nitrogen atoms;
R2 is H, -OR3;
R3 is H or a Cj-C24 straight or branched, saturated or unsaturated acyl residue;
R4 is H, straight or branched Cj-C4 alkyl, hydroxyalkyl, aminoalkyl or cyano;
R5 and R6 can be H, -OH or -OCH3.
Among the polyamines indicated for the R1 function, spermine and
spermidine are preferred. If the polyamine nitrogen atoms are not acylated, the product is salified with suitable organic or inorganic acids, preferably trifluoroacetic, oxalic, tartaric or hydrochloric acid.
The 17- position is preferably esterified with activated derivatives of acetic, ximeninic, c/s-4,7, 10, 13, 16, 19- docosahexenoic or c/s-5,8, 1 1, 14- eicosapentaenoic acid.
The products of the invention are usually synthesized from camptothecin, or from analogues thereof suitably functionalized at the 7-, 9- and 10- positions by reaction with a suitably protected polyamine. The reaction is usually performed in polar aprotic solvents, in the presence of a base. Upon completion of the reaction the mixture is neutralized with acids and extracted with an organic solvent. The crude obtained after evaporation of the solvent can be purified or used as such for subsequent functionalization at the 17- position. The polyamine is preferably protected with a t-butoxycarbonyl (Boc) or a carbobenzyloxy (CBz) group. The protected polyamine is prepared as described in literature.
The esterification of the 17- position is preferably performed on the crude precursor by acylation with the selected acyl chloride in pyridine. The removal of the 17-hydroxy group is instead accomplished by hydrogenolysis with Pd(C) in methanol under the conditions described in greater detail in the examples.
A simplified procedure for the preparation of the salts consists in the use of CBz protected polyamines, and deprotection through hydrogenation in the presence of stoichiometric amounts of the selected acids. Although the integrity of the E-ring is commonly deemed crucial for the cytotoxic activity of camptothecin analogues, the compounds of the present invention maintain an interesting cytotoxic in vitro activity and still inhibit topoisomerase I.
As far as in vivo activity is concerned, the products of the invention show activity against the H460 lung tumor model comparable to substances are already used in clinic, such as topotecan, and other active principles currently under clinical investigation. However, the advantage of the compounds of the invention consists in lower toxicity compared with known products and in higher tolerability, which allow a broader therapeutic window.
The products can be incorporated into the most common pharmaceutical forms, either injectable or oral. The examples reported hereinbelow illustrate the invention.
Example I - Preparation of compound A
N2,N3-Di-t-butoxycarbonylspermidine (2.8 g, 8.1 mmol), prepared according to the procedures reported in literature, is added to a suspension of camptothecin (700 mg, 2.01 mmol) in dry pyridine (50 ml), under nitrogen atmosphere. The reaction mixture is heated to 8O0C to obtain a clear yellow mixture. After 3 days at 8O0C the mixture is cooled and washed with 5% HCl, extracted with CHCl3 and dried over Na2SO4. After evaporation of the solvent, the crude product is purified through flash chromatography (silica gel, CHCl3: CH3OH 96: 4) to give the desired compound as a pale yellow solid (730 mg, 52%). 1H-NMR (CDCl3): δ 1.15 (t, 3H), 1.25 (4H), 1.45 (18H), 1.65 (2H), 2.39 (m, 2H), 3.1 (4H), 3.25 (m, 4H), 4.35 (d, IH, J=13.2), 5.0 (d, IH, J= 13.2, 5.15 (2H), 7.5-8.2 (6H).
Example II - Preparation of compound B
The product of example I (570 mg, 0.82 mmol) is reacted with acetic anhydride (1.54 ml) in 1.65 ml of dry pyridine to give the desired compound as a yellow solid (488 mg, 81%).
1H-NMR (CDCl3): δ 1.15 (t, 3H, J-6.9), 1.2 (6H), 1.45 (18H), 2.05 (s, 3H), 2.35 (m, 2H), 3.05 (4H), 3.2 (4H), 5.25 (s, 2H), 5.4 (2H), 7.5-8.4
(6H).
13C-NMR (CDCl3): δ 7.87 (q), 20.97 (q), 25.66 (t), 2x27.39 (t), 6x28.37
(q), 32.93 (t), 40.15 (t), 3x46.58 (t), 50.2 (t), 58.98 (t), 78.74 (s), 79.64 (s),
100.6 (d), 125.0 (s). 127.72 (d), 127.89 (d), 2x128.35 (s), 129.32 (d), 130.19 (d), 130.61 (d), 2x144.47 (s), 2x148.45 (s), 2x155.97 (s), 161.58 (s), 2x171.15
(S).
HPLC (RP 8; 75% H2O, 25% CH3CN): 18.47 min. Example III - Preparation of compound C
The product of example II (488 mg, 0.664 mmol) is dissolved in anhydrous CH2Cl2 and deprotected by adding, drop by drop, trifluoroacetic acid (0.8 ml) at 00C under nitrogen atmosphere. The reaction mixture is stirred at 00C for 1.5 h, then the solvent is evaporated off under reduced pressure. The residue is dissolved in CHCl3 and precipitated from «-hexane. The desired compound is obtained as a yellow solid (505 mg, 98%). 1H NMR (DMSO-d6/D2O) δ 8.63 (s, 1 H, arom), 8.12 (d, 1 H, J = 8.4
Hz arom), 8.05 (d, 1 H, J = 8.4 Hz arom), 7.86-7.81 (m, 1 H, arom), 7.70-7.65 (m, 1 H, arom), 7.50 (s, 1 H, arom), 5.29 (d, 1 H, CH2-O, J = 11.2 Hz), 5.24 (d, 1 H, CH2-O, J - 1 1.2 Hz), 5.21 (s, 2 H, CH2-N), 3.20-3.00 (m, 2 H), 2.88-2.80 (m, 4 H), 2.80-2.72 (m, 2 H), 2.18-2.28 (m, 1 H), 2.06-2.18 (m, 1 H), 1.95 (s, 3 H, Me, OAc), 1.76-1.66 (m, 2 H), 1.60- 1.48 (m, 4 H), 0.88 (t, 3 H, J = 7.8 Hz, Me).
13C NMR (DMSO-d6) δ 173.9, 171.0, 161.3, 158.0 (q, CO2H of TFA), 156.5, 153.4, 148.7, 144.9, 132.3, 131.1, 130.6, 129.7, 1292, 128.7, 128.3, 124.0, 99.5, 79.4, 59.5, 51.0, 46.8, 45.3, 38.9, 36.7, 32.3, 26.5, 24.8, 23.3, 21.4, 8.6.
Example IV - Preparation of compound D
A suspension of 7-ethylcamptothecin (3 g, 7.9 mmol) in dry pyridine is added with N2,N3-dibenzyloxycarbonylspermidine (6.5 g, 15 mmol). The
mixture is sonicated at 55°C for 12 hrs. Pyridine is then removed by distillation under reduced pressure at room temperature and the residue is dissolved in dichloromethane (20 ml), washed with a 5% citric acid solution (2x50 ml) and then with water (20 ml). After drying over Na2SO4 and filtering, the mixture is evaporated to obtain crude compound D (7.5 g), which is purified through flash-chromatography (silica gel, CHCl3 :CH3OH 96: 4) or is used as such for the subsequent reaction.
Example V - Preparation of compound E
The crude product obtained from example IV (7.5 g, 9.6 mmol) is acetylated with acetic anhydride (9.12 g) in dry pyridine (8.6 ml). The reaction is left under stirring overnight at room temperature and under nitrogen atmosphere. The mixture is then poured into ice-water (40 ml) and extracted with methylene chloride (2x30 ml). After evaporation of the solvent, the product is purified through flash chromatography using 98:2 ethyl acetate and methanol. 3.5 g of a yellow solid product are obtained.
Example VI - Preparation of compound F
A solution of compound E (166 mg, 0.2 mmol) in acetonitrile (20 ml) is added with 5% Pd/C (100 mg) and L-(+)-tartaric acid (60 mg, 0.4 mmol). The mixture is hydrogenated at 4 atmospheres for 3 hours. Upon completion of the reaction the mixture is filtered through syntherized glass. The filtrate is concentrated to give compound F (140 mg, 98.5%).
1H NMR (DMSO-d6/D2O) δ 8.26 (d, 1 H, J = 8.4 Hz, arom), 8.17 (d, 1 H, J - 8.4 Hz, arom), 8.10-8.05 (m, 1 H, NHC=O), 7.83 (m, 1 H, arom), 7.71 (m, 1 H, arom), 7.48 (s, 1 H, arom), 5.38 (d, 1 H, CH2O, J - 1 1.0 Hz), 5.32 (d, 1 H, CH2O, J = 1 1.0 Hz), 5.27 (s, 2 H, CH2N), 3.97 (s, 4 H of tartaric acid, 2 CH2), 3.24- 3.10 (m, 4 H, CH2 Of C7-Et and CH2 Of CH2N-C=O), 2.90-2.70 (m, 6 H, 3 CH2), 2.30-2.00 (m, 2 H, CH2 of C19-H2), 1.97 (s, 3 H, Me, OAc), 1.80- 1.68 (m, 2 H, CH2), 1.68- 1.50 (m, 4 H, 2 CH2), 1.30 (t, 3 H, Me of
C7-Et), 0.87 (t, 3 H, Me at C18).
Example VII - Preparation of compounds G and H
Product E (500 mg, 0.6 mmol) is hydrogenated in the presence of succinic acid (142 mg, 1.2 mmol) in acetonitrile (20 ml) over 5% Pd/C (165 mg), using the same procedure as in example VI. Compounds G and H are obtained as 1 : 1 mixture with 91% overall yield. The products are separated by flash chromatography.
Compound G
1H NMR (DMSO-d6/D2O) δ 8.19 (d, 1 H, J = 8.5 Hz, arom), 8.09 (d, 1 H, J = 8.5 Hz, arom), 7.82-7.77 (m, 1 H, arom), 7.69-7.64 (m, 1 H, arom),
7.45 (s, 1 H, arom), 5.18 (s, 2 H, CH2N), 3.10-3.2 (m, 4 H, CH2 Of C7-Et and
CH2-NHC=O), 2.80-2.70 (m, 6 H, 3 CH2), 2.28 (s, 4 H, 2 CH2 of succinic acid), 2.23 (s, 3 H, Me), 2.30-2.10 (m, 2 H, CH2 of C2O-Et), 1.70- 1.50 (m,
6 H, 3 CH2), 1.27 (t, 3 H, Me of C7-Et), 0.87 (t, 3 H, Me at C18). 13C NMR (DMSO) δ 175.8 (C of succinic acid), 173.7 (C), 161.8 (C),
153.4 (C), 152.1 (C), 149.2 (C), 146.0 (C), 142.1 (C), 130.5 (CH), 128.4 (CH),
128.0 (C), 127.8 (2 CH), 127.0 (C), 124.7 (CH), 99.9 (CH), 78.8 (C), 50.0
(CH2N), 48.0 (CH2), 46.3 (CH2), 38.8 (CH2) 36.6 (CH2), 32.1 (CH2, succinic acid), 31.5 (CH2), 26.8 (CH2), 24.8 (CH2), 23.7 (CH2), 22.9 (CH2), 20.3 (Me), 14.6 (Me), 8.6 (Me)
Compound H
1H NMR (DMSO-d6/D2O) δ 8.26 (d, 1 H, J = 8.4 Hz, arom), 8.17 (d, 1 H, J = 8.4 Hz, arom), 8.10-8.05 (m, 1 H, NHC=O), 7.83 (m, 1 H, arom), 7.71 (m, 1 H, arom), 7.48 (s, 1 H, arom), 5.38 (d, 1 H, CH2O, J = 1 1.0 Hz), 5.32 (d, 1 H, CH2O, J - 1 1.0 Hz), 5.27 (s, 2 H, CH2N), 3.97 (s, 4 H of tartaric acid, 2 CH2), 3.24- 3.10 (m, 4 H, CH2 Of C7-Et and CH2 Of CH2N-C=O), 2.90-2.70 (m, 6 H, 3 CH2), 2.30-2.00 (m, 2 H, CH2 of C19-H2), 1.97 (s, 3 H, Me, OAc), 1.80- 1.68 (m, 2 H, CH2), 1.68- 1.50 (m, 4 H, 2 CH2), 1.30 (t, 3 H, Me of
C7-Et), 0.87 (t, 3 H, Me at C18).
Example VIII - Preparation of compound I
Product E (400 mg, 0.48 mmol) is hydrogenated over 5% Pd/C (5%) (100 mg) in the presence of oxalic acid (121 mg, 0.96 mmol) in acetonitrile (20 mL) using the same procedure as in example VI. 234 mg (74.7%) of product I are obtained.
1H NMR (DMSO-d6/D2O) δ 8.26 (d, 1 H, J = 8.4 Hz, arom), 8.16 (d, 1 H, J = 8.4 Hz, arom), 8.10-8.00 (m, 1 H, NHC=O), 7.83 (m, 1 H, arom), 7.71 (m, 1 H, arom), 7.47 (s, 1 H, arom), 5.36 (d, 1 H, CH2O, J = 11.0 Hz), 5.31 (d, 1 H, CH2O, J = 11.0 Hz), 5.27 (s, 2 H, CH2N), 3.24- 3.14 (m, 4 H, CH2 of C7-Et and CH2 Of CH2N-C=O), 2.90-2.70 (m, 6 H, 3 CH2), 2.30-2.00 (m, 2 H, CH2 of C19-H2), 1.97 (s, 3 H, Me, OAc), 1.82- 1.68 (m, 2 H, CH2), 1.68-1.50 (m, 4 H, 2 CH2), 1.31 (t, 3 H, Me of 7-Et), 0.87 (t, 3 H, Me at C18). Example IX - Preparation of compound J Product D (570 mg, 0.82 mmol) is esterified with cis-4,7, 10, 13, 16, 19- docosahexenoyl chloride in dry pyridine (2.65 ml). After purification through flash chromatography product J is obtained as a yellow solid (550 mg).
1H NMR (CD3OD, 400 MHz) δ 8.54 (s, 1 H, Ar), 8.10 (d, 1 H, J = 8.4 Hz, Ar), 7.99 (d, 1 H, J = 8.4 Hz, Ar), 7.84-7.79 (m, 1 H, Ar), 7.78 (s, 1 H, H- 14), 7.69-7.63 (m, 1 H, Ar), 5.50 (d, 1 H, J = 1 1.2 Hz, H- 17), 5.43 (d, 1 H, J = 1 1.2 Hz, H- 17), 5.41-5.24 (m, 12 H), 5.20 (s, 2 H, H-5), 3.14-2.92 (m, 8 H, 4 CH2), 2.86-2.72 (m, 10 H, 5 CH2), 2.50-2.38 (m, 4 H, 2 CH2), 2.38-2.24 (m, 1 H, H), 2.10-2.00 (m, 3 H, CH2+H), 1.98- 1.89 (m, 2 H, CH2), 1.86-1.69 (m, 4 H, 2 CH2), 1.06 (t, 3 H, J = 7.2 Hz, CH3), 0.93 (t, 3 H, J = 7.2 Hz, CH3). 13C NMR (CD3OD, 100 MHz) δ 175.5 (CO), 173.9 (CO), 162.1 , 161.8,
157.1 (NCO), 152.5, 148.4, 144.8, 132.1 , 131.6, 130.7, 129.6, 129.0, 128.7, 128.6, 128.5, 128.3, 128.1 , 128.0, 128.0, 127.9, 127.8, 127.8, 127.7, 127.0, 124.4, 100.9 (C- 14), 79.1 (C), 59.2 (C- 17), 50.5, (C-5), 47.1, 45.4, 38.8, 36.7,
34.0, 32.1, 26.4, 25.4, 25.3, 25.2, 24.4, 24.3, 24.2, 23.1 , 23.0, 22.7, 20.3, 13.5 (Me), 7.2 (Me).
Example X - Preparation of compound L
The product of example II (488 mg, 0.664 mmol) is dissolved in methylene chloride and deprotected with formic acid (0.8 ml) at O0C under nitrogen atmosphere. The reaction mixture is stirred at O0C for 8 h, then the solvent is evaporated off under reduced pressure. The residue is dissolved in CHCl3 and precipitated from «-hexane. The desired compound is obtained as a yellow solid (90%). 1H NMR (DMSO) δ 8.64 (s, 1 H, arom), 8.20-8.40 (s, 1 H arom),
8.02-8.20 (m, 2 H, arom), 7.84 (m, 1 H, arom), 7.68 (m, 1 H, arom), 7.50 (s, 1 H, arom), 5.37 (d, 1 H, CH2-O, J = 8.0 Hz), 5.31 (d, 1 H, CH2-O, J = 8.0 Hz), 5.24 (s, 2 H, CH2-N), 3.24-3.12 (m, 1 H), 3.10-3.00 (m, 1 H), 2.80-2.60 (m, 6 H), 2.20-2.12 (m, 1 H), 2.12-2.04 (m, 1 H), 1.96 (s, 3 H, Me), 1.70- 1.60 (m, 2 H), 1.60- 1.44 (m, 4 H), 0.87 (t, 3 H, J = 7.5 Hz, Me).
13C NMR (DMSO) δ 173.7, 171.0. 166.4 (C-O of HCO2H), 161.3, 156.6, 153.4, 148.7, 144.7, 132.2, 131.0, 130.6, 129.7, 129.2, 128.6, 128.2, 124.0, 99.6, 79.6, 59.5, 50.9, 47.6, 46.0, 39.0, 37.3, 32.3, 27.8, 25.8, 25.0, 21.4, 8.6.
Claims
1. Compounds of the general formula (I)
(I) in which
R1 is a straight or branched polyamino residue, optionally functionalized by acylation or alkylation of the amino residues, with more than 2 nitrogen atoms;
R2 is H, -OR3;
R3 is H or a Ci -C24 straight or branched, saturated or unsaturated acyl residue;
R4 is H, straight or branched Ci -C4 alkyl, hydroxyalkyl, aminoalkyl, cyano;
R5 and R6 are H, -OH or -OCH3.
2. Compounds as claimed in claim 1 wherein the polyamine is spermidine, protected spermidine or salified spermidine.
4. Compounds as claimed in claim 2 in which the polyamine is N2,N3-Di- Cbz-spermine.
5. Compounds as claimed in claim 2 in which the polyamine is salified spermine.
6. Compounds as claimed in any one of claims 1 to 5 in which the R3 residue is acetyl.
7. Compounds as claimed in any one of claims 1 to 5 in which the R3 residue is cw-4,7,10,13,16,19-docosahexenoyl. 8. Compounds as claimed in any one of claims 1 to 5 in which the R3 residue is cz5-5,
8,l l, 14-eicosapentaenoyl.
9. Compounds as claimed in any one of claims 1 to 5 in which the R3 residue is ximeninoyl.
10. Pharmaceutical compositions comprising as active ingredient a compound of any one of claims 1-9 in admixture with suitable carriers and excipients.
11. The use of the compounds of any one of claims 1-9 for the preparation of anti-tumour medicaments.
12. Compounds of claims 1-9 as medicaments.
13. Compounds of claims 1-9 as anti-tumour agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT001348A ITMI20051348A1 (en) | 2005-07-14 | 2005-07-14 | ANALOGUES OF CAMPTOTECINE THEIR PROCESS OF OBTAINING THEIR USE AND FORMULATIONS THAT CONTAIN THEM |
ITMI2005A001348 | 2005-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007006543A1 true WO2007006543A1 (en) | 2007-01-18 |
Family
ID=37027919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/006760 WO2007006543A1 (en) | 2005-07-14 | 2006-07-11 | Camptothecin analogues, process for their preparation, use and formulations containing them |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITMI20051348A1 (en) |
WO (1) | WO2007006543A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0700914A1 (en) * | 1994-09-06 | 1996-03-13 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives, preparations thereof and antitumor agents |
WO1997043290A1 (en) * | 1996-05-10 | 1997-11-20 | Indena S.P.A. | Camptothecin-skeleton compounds isolated from mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents |
-
2005
- 2005-07-14 IT IT001348A patent/ITMI20051348A1/en unknown
-
2006
- 2006-07-11 WO PCT/EP2006/006760 patent/WO2007006543A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0700914A1 (en) * | 1994-09-06 | 1996-03-13 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives, preparations thereof and antitumor agents |
WO1997043290A1 (en) * | 1996-05-10 | 1997-11-20 | Indena S.P.A. | Camptothecin-skeleton compounds isolated from mappia foetida and the use thereof as syntones for novel medicaments as well as therapeutical agents |
Also Published As
Publication number | Publication date |
---|---|
ITMI20051348A1 (en) | 2007-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0406274B1 (en) | Water soluble, antineoplastic derivatives of taxol | |
ES2667054T3 (en) | New substituted imidazoquinolines | |
JP6501742B2 (en) | Preuro mutilin | |
EP0418099A2 (en) | 10, 11-Methylenedioxy-20 (RS) camptothecin and 10, 11-methylenedioxy-20 (S) - camptothecin analog | |
BRPI0110801B1 (en) | ANTITUMAL ANALOGS OF ET-743, PHARMACEUTICAL COMPOSITION UNDERSTANDING THE SAME AND USE OF THESE ANALOGS | |
PT749432E (en) | 9-DEOXOTAXANE COMPOUNDS | |
EP0840738B1 (en) | Colchicine derivatives, the use thereof and formulations containing them | |
JPH10503220A (en) | Substituted camptothecin derivatives and method for producing the same | |
EP1791539A1 (en) | Process to prepare camptothecin derivatives | |
AU2003241161C1 (en) | Esters in position 20 of camptothecins | |
CA2721140A1 (en) | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | |
AU666626B2 (en) | 1-aryloxy-3-alkylamino-2-propanol nitrate esters, the use thereof and corresponding pharamceutical composition | |
RU2450007C2 (en) | Camptothecin derivatives with anticancer activity | |
WO1997028164A1 (en) | 9,10 disubstituted camptothecin derivatives with antitumor activity | |
WO2007006543A1 (en) | Camptothecin analogues, process for their preparation, use and formulations containing them | |
DE69503213T2 (en) | Baccatin derivatives and process for their preparation | |
RU2169149C2 (en) | Compounds with camptothecin structure, methods of their synthesis, pharmaceutical compositions | |
CA2528223C (en) | Colchicoside analogues | |
JPS62195384A (en) | Novel camptothecin derivative | |
JP2020530441A (en) | Synthesis of aza sugars and their intermediates | |
CN113292627B (en) | NQO1 targeted indoloquinones 23-hydroxy betulinic acid derivatives, preparation method and application | |
CN112778393B (en) | Oleandrin derivatives, and preparation method, pharmaceutical composition and application thereof | |
JPH06211762A (en) | N-methyldeacetylcolchiceinamide derivative | |
MX2010011079A (en) | Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof. | |
JP5863846B2 (en) | Method for producing irinotecan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06776189 Country of ref document: EP Kind code of ref document: A1 |